Core Insights - Aveanna Healthcare Holdings Inc. has successfully closed a refinancing of its first lien credit facility, which includes refinancing $886.0 million in existing loans and an additional $439.0 million in incremental loans, increasing the revolving credit facility from $170.3 million to $250.0 million [1][2] - The maturity dates for the combined $1.325 billion first lien term loans have been extended to 2032, while the revolving credit facility's maturity has been extended to 2030 [1] - The incremental loans were utilized to fully repay existing second lien term loans amounting to $415.0 million, leading to the termination of the second lien term loan facility [2] Company Performance - The refinancing is viewed as a significant milestone in the company's ongoing momentum, enhancing liquidity and strengthening the balance sheet [3] - The Chief Financial Officer highlighted that the refinancing reflects the strong operating performance and the confidence of financing partners in the company's business [3] - The CEO emphasized the successful refinancing as a testament to the operating performance and the value of the national home care platform [3] Company Overview - Aveanna Healthcare is based in Atlanta, Georgia, and operates in 38 states, offering a wide range of pediatric and adult healthcare services, including nursing, rehabilitation, and therapy services [4] - The company provides case management services to assist families and patients in coordinating care among various healthcare providers [4] - Aveanna also offers respite healthcare services, which provide temporary relief for normal caregivers, aiming to deliver high-quality, lower-cost alternatives to prolonged hospitalization [4]

Company Performance - Aveanna Healthcare (AVAH) has seen a stock increase of 16.9% over the past month, reaching a new 52-week high of $8.45 [1] - Year-to-date, Aveanna's stock has gained 84.3%, significantly outperforming the Zacks Medical sector, which has seen a decline of 0.7%, and the Zacks Medical - Outpatient and Home Healthcare industry, which has returned 10.3% [1] Earnings and Revenue - Aveanna has a strong record of positive earnings surprises, having met or exceeded earnings consensus estimates in the last four quarters [2] - In the latest earnings report on August 7, 2025, Aveanna reported an EPS of $0.18, surpassing the consensus estimate of $0.04, and beat the revenue estimate by 9.93% [2] - For the current fiscal year, Aveanna is projected to post earnings of $0.41 per share on revenues of $2.31 billion, reflecting a 600% increase in EPS and a 14.24% increase in revenues [3] - For the next fiscal year, expected earnings are $0.48 per share on revenues of $2.43 billion, indicating year-over-year changes of 15.48% and 5.07%, respectively [3] Valuation Metrics - Aveanna's current valuation metrics show a Price-to-Earnings (P/E) ratio of 20.3X for the current fiscal year, slightly below the peer industry average of 20.7X [7] - On a trailing cash flow basis, Aveanna trades at 51.4X compared to the peer group's average of 18.1X, suggesting it is not in the top echelon from a value perspective [7] Zacks Rank and Style Scores - Aveanna holds a Zacks Rank of 1 (Strong Buy) due to rising earnings estimates, which aligns with the recommendation for investors to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [8] - The company has a Value Score of B, a Growth Score of A, and a Momentum Score of C, resulting in a combined VGM Score of A [6] Industry Comparison - The Medical - Outpatient and Home Healthcare industry ranks in the bottom 61% of all industries, but Aveanna and its peer, Encompass Health Corporation (EHC), show potential for growth despite the overall industry ranking [11] - EHC has a Zacks Rank of 2 (Buy) and has reported strong earnings, with expected earnings of $5.24 per share on revenues of $5.92 billion for the current fiscal year [10]

ATLANTA, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Jefferies Healthcare Services Conference in Nashville on September 30, 2025. Management will host 1x1 investor meetings as well as a fireside chat at 3:00 p.m. Central Time on the same day, September 30, 2025. Interested investors and other parties may also listen to a simultaneous webcast of the fireside chat by logging onto the Investor Relations ...

Core Viewpoint - Aveanna Healthcare Holdings Inc. (AVAH) is showing potential for a bullish breakout due to a recent technical indicator known as a "golden cross" [1][2]. Technical Analysis - AVAH's 50-day simple moving average has crossed above its 200-day simple moving average, indicating a bullish signal [1]. - A golden cross typically follows a downtrend, leading to a positive trend reversal and subsequent upward momentum [2]. Performance Metrics - AVAH has experienced a significant rally of 88.6% over the past four weeks, suggesting strong market interest [3]. - The company currently holds a 1 (Strong Buy) rating on the Zacks Rank, indicating favorable market conditions for potential gains [3]. Earnings Outlook - The earnings outlook for AVAH is positive, with no downward revisions in earnings estimates over the past two months, alongside four upward revisions [3]. - The Zacks Consensus Estimate for earnings has also increased, reinforcing the bullish sentiment around the stock [3][5]. Investment Consideration - Given the combination of positive earnings revisions and the technical breakout signal, AVAH is positioned for potential further gains in the near future [5].

Company Performance - Aveanna Healthcare (AVAH) has seen a significant stock increase of 88.6% over the past month, reaching a new 52-week high of $7.69 [1] - Year-to-date, Aveanna's stock has gained 63.5%, outperforming the Zacks Medical sector, which declined by 1.4%, and the Zacks Medical - Outpatient and Home Healthcare industry, which returned 9% [1] Earnings and Revenue - Aveanna has consistently exceeded earnings expectations, reporting an EPS of $0.18 against a consensus estimate of $0.04 in its last earnings report on August 7, 2025, and beating revenue estimates by 9.93% [2] - For the current fiscal year, Aveanna is projected to achieve earnings of $0.41 per share on revenues of $2.31 billion, reflecting a 600% increase in EPS and a 14.24% increase in revenues [3] - The next fiscal year forecasts earnings of $0.48 per share on revenues of $2.43 billion, indicating year-over-year changes of 15.48% and 5.07%, respectively [3] Valuation Metrics - Aveanna's current valuation metrics show a Price-to-Earnings (P/E) ratio of 18X for the current fiscal year, below the peer industry average of 20.3X, while its trailing cash flow basis P/E is 45.6X compared to the peer group's average of 17.9X [6] - The stock has a Value Score of B, with Growth and Momentum Scores both rated A, resulting in a combined VGM Score of A [6] Zacks Rank - Aveanna holds a Zacks Rank of 1 (Strong Buy), driven by rising earnings estimates, making it a favorable choice for investors [7] - The recommendation is to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B, which Aveanna meets [7] Industry Comparison - The Medical - Outpatient and Home Healthcare industry is performing well, ranking in the top 18% of all industries, providing favorable conditions for both Aveanna and its peer, Encompass Health Corporation (EHC) [10] - EHC has a Zacks Rank of 2 (Buy) and has also shown strong earnings performance, beating consensus estimates by 16.67% [9]

Core Viewpoint - Aveanna Healthcare (AVAH) is experiencing significant improvements in earnings estimates, which may lead to continued stock price momentum [1][2] Estimate Revisions - The trend in estimate revisions reflects growing analyst optimism regarding Aveanna's earnings prospects, which is expected to positively impact its stock price [2] - For the current quarter, Aveanna is projected to earn $0.06 per share, marking a 200.0% increase from the previous year [6] - Over the last 30 days, the Zacks Consensus Estimate for Aveanna has surged by 850%, with three estimates moving higher and no negative revisions [6] - For the full year, the earnings estimate is $0.35 per share, representing a 483.3% increase from the prior year [7] - The consensus estimate for the current year has increased by 195.35% during this period [8] Zacks Rank - Aveanna has achieved a Zacks Rank 1 (Strong Buy) due to favorable estimate revisions, indicating strong potential for stock performance [9] - The Zacks Rank system has a proven track record, with Zacks 1 Ranked stocks generating an average annual return of +25% since 2008 [3] Stock Performance - Aveanna's stock has gained 80.9% over the past four weeks, driven by solid estimate revisions and positive earnings growth prospects [10]

Group 1: Momentum Investing Overview - Momentum investing involves following a stock's recent trend, with the strategy of buying high and selling higher, capitalizing on established price movements [1] - The Zacks Momentum Style Score helps investors identify stocks with momentum by focusing on key metrics [2] Group 2: Aveanna Healthcare (AVAH) Analysis - Aveanna Healthcare currently holds a Momentum Style Score of A and a Zacks Rank of 1 (Strong Buy), indicating strong potential for outperformance [3][4] - Over the past week, AVAH shares increased by 15.31%, significantly outperforming the Zacks Medical - Outpatient and Home Healthcare industry, which rose by 1.01% [6] - In a longer timeframe, AVAH shares have risen by 33.4% over the past quarter and 42.27% over the past year, while the S&P 500 only increased by 7.87% and 15.7%, respectively [7] Group 3: Trading Volume and Earnings Outlook - The average 20-day trading volume for AVAH is 1,672,211 shares, indicating a bullish sign with rising stock prices [8] - Over the past two months, three earnings estimates for AVAH have increased, raising the consensus estimate from $0.22 to $0.35 [10] - The positive earnings revisions suggest a promising outlook for AVAH, reinforcing its status as a 1 (Strong Buy) stock with a Momentum Score of A [12]

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than the traditional "buying low and selling high" approach, aiming for quicker profits [1] Group 1: Momentum Investing Characteristics - Momentum investing can be risky as stocks may lose momentum if their valuations exceed future growth potential, leading to potential losses for investors [2] - A safer strategy involves investing in bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score to identify such opportunities [3] Group 2: Aveanna Healthcare (AVAH) Analysis - Aveanna Healthcare (AVAH) has shown significant price movement, with a 74.7% increase over the past four weeks, indicating strong investor interest [4] - Over the past 12 weeks, AVAH's stock has gained 32.3%, demonstrating its ability to maintain momentum over a longer period [5] - AVAH has a beta of 1.95, suggesting it moves 95% more than the market, indicating fast-paced momentum [5] - The stock has a Momentum Score of B, suggesting it is an opportune time for investment to capitalize on its momentum [6] - AVAH has received a Zacks Rank 1 (Strong Buy) due to upward revisions in earnings estimates, which typically attract more investors [7] - The stock is currently trading at a Price-to-Sales ratio of 0.68, indicating it is undervalued, as investors pay only 68 cents for each dollar of sales [7] Group 3: Additional Investment Opportunities - Besides AVAH, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting further investment opportunities [8] - Investors can explore over 45 Zacks Premium Screens tailored to different investing styles to identify potential winning stocks [9]

Company Overview - Aveanna Healthcare Holdings Inc. is headquartered in Atlanta, Georgia and operates in 38 states, providing a wide range of pediatric and adult healthcare services [2] - Services include nursing, rehabilitation, occupational nursing in schools, therapy services, day treatment centers for medically fragile and chronically ill patients, home health and hospice services, and delivery of enteral nutrition [2] - The company also offers case management services to coordinate care among insurers, physicians, hospitals, and other healthcare providers, as well as respite healthcare services for temporary caregiver relief [2] Upcoming Events - The management team of Aveanna will attend the Deutsche Bank Healthcare Summit in New York on September 10, 2025, and will host one-on-one investor meetings on that day [1]

Company Performance - Akero Therapeutics, Inc. (AKRO) has shown a year-to-date performance increase of approximately 73.5%, significantly outperforming the average loss of 7.5% in the Medical sector [4] - The Zacks Consensus Estimate for AKRO's full-year earnings has increased by 1.4% over the past quarter, indicating improved analyst sentiment and a stronger earnings outlook [3] Industry Comparison - Akero Therapeutics, Inc. is part of the Medical - Biomedical and Genetics industry, which consists of 489 companies and currently ranks 141 in the Zacks Industry Rank. This industry has experienced a slight decline of about 0.9% year-to-date, further highlighting AKRO's superior performance [6] - In contrast, Aveanna Healthcare (AVAH), another outperforming stock in the Medical sector, belongs to the Medical - Outpatient and Home Healthcare industry, which has seen a year-to-date increase of 3.8% and ranks 40 [7]